Novartis debuts €40M viral vector plant in Slovenia, part of €3.5B investment push in the country
Novartis opened the doors to a €40 million ($41.2 million) viral vector facility in Mengeš, Slovenia, boosting the drugmaker’s investment in the country so far to €3.5 billion ($3.6 billion). The move forms part of Novartis' greater ambition to expand production of new cell and gene therapies in Europe.
Novartis opened the doors to a €40 million ($41.2 million) viral vector facility in Mengeš, Slovenia, boosting the drugmaker’s investment in the country so far to €3.5 billion ($3.6 billion). The move forms part of Novartis' greater ambition to expand production of new cell and gene therapies in Europe.
